Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions


Pharmaceutical Technology



Figure 2
in which A is the liquid-phase reactant, G is the dissolving gas, P is the product, and BP the byproduct (19). This could be a generic network corresponding to a hydrogenation and overhydrogenation. A typical result of our study is shown in Figure 3, which plots the selectivity Y P toward the reaction as a function of the bubble Reynolds number. The initial decrease of Y P coincides with the onset of recirculation. Recirculation leads to a significantly increased residence time of the product P in the wake and reduces the concentration of the reactant A in the wake. Effectively, the recirculating pattern in the wake acts as a barrier for reactant A, which cannot enter the wake. Thus, because the concentration of A is low, a larger fraction of the gas G reacts with P to form the secondary product BP, leading to a decrease of the selectivity. At Reynolds numbers greater than 52, vortex shedding occurs, which causes a sudden increase of selectivity (see Figure 3). Once vortex shedding occurs, patches of the dissolved gas G (and product P) are quickly convected away from the bubble into regions rich in A, thus leading to significantly higher selectivities toward P. In effect, the transition from a closed wake to an open wake qualitatively changes the mixing behavior, which can lead to a large change in the reaction selectivity.


Figure 3
This study involves a similar reaction network to prove our computational results experimentally. For safety reasons, however, a liquid–liquid system was chosen in favor of a gas–liquid reaction.

Experiment

Reaction and chemicals. To verify the computationally predicted effects previously published (19–22), an extensive series of experiments was performed. The iodination of l-tyrosine to form 3-iodo-l-tyrosine and 3,5-diiodo-l-tyrosine was studied in a liquid–liquid system. This is a competitive-consecutive second-order reaction, previously studied in a single liquid phase by Paul and Treybal (11), that occurs naturally within the human body. The compound l-tyrosine aids in the production of thyroid hormones by acting as a carrier and allowing iodine to enter the thyroid cells. Figure 4 shows the reaction system.


Figure 4
We purchased 98% pure l-tyrosine from Sigma Aldrich (St. Louis, MO). Samples of 3-iodo-l-tyrosine and 3,5-diiodo-l-tyrosine were also purchased from Sigma Aldrich for use as standards for high-performance liquid chromatography (HPLC). All other chemicals (sodium hydroxide, potassium iodide, iodine, sodium phosphate dibasic, sodium phosphate tribasic dodecahydrate, methylene chloride, and glycerin) were purchased from either Fisher Scientific or Sigma Aldrich and were a minimum of 98% pure.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here